Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.

Krug, Lee M ; Kindler, Hedy L ; Calvert, Hilary ; Manegold, Christian ; Tsao, Anne S ; Fennell, Dean ; Öhman, Ronny LU ; Plummer, Ruth ; Eberhardt, Wilfried E E and Fukuoka, Kazuya , et al. (2015) In The Lancet Oncology 16(4). p.447-456
Abstract
Vorinostat is a histone deacetylase inhibitor that changes gene expression and protein activity. On the basis of the clinical benefit reported in patients with malignant pleural mesothelioma treated in a phase 1 study of vorinostat, we designed this phase 3 trial to investigate whether vorinostat given as a second-line or third-line therapy improved patients' overall survival.
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
The Lancet Oncology
volume
16
issue
4
pages
447 - 456
publisher
Elsevier
external identifiers
  • pmid:25800891
  • wos:000352020000051
  • scopus:84933526775
ISSN
1474-5488
DOI
10.1016/S1470-2045(15)70056-2
language
English
LU publication?
yes
id
68518d96-46b7-4406-9f98-24f7eb71bf72 (old id 5257808)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25800891?dopt=Abstract
date added to LUP
2016-04-01 11:06:52
date last changed
2022-04-28 07:15:28
@article{68518d96-46b7-4406-9f98-24f7eb71bf72,
  abstract     = {{Vorinostat is a histone deacetylase inhibitor that changes gene expression and protein activity. On the basis of the clinical benefit reported in patients with malignant pleural mesothelioma treated in a phase 1 study of vorinostat, we designed this phase 3 trial to investigate whether vorinostat given as a second-line or third-line therapy improved patients' overall survival.}},
  author       = {{Krug, Lee M and Kindler, Hedy L and Calvert, Hilary and Manegold, Christian and Tsao, Anne S and Fennell, Dean and Öhman, Ronny and Plummer, Ruth and Eberhardt, Wilfried E E and Fukuoka, Kazuya and Gaafar, Rabab M and Lafitte, Jean-Jacques and Hillerdal, Gunnar and Chu, Quincy and Buikhuisen, Wieneke A and Lubiniecki, Gregory M and Sun, Xing and Smith, Margaret and Baas, Paul}},
  issn         = {{1474-5488}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{447--456}},
  publisher    = {{Elsevier}},
  series       = {{The Lancet Oncology}},
  title        = {{Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.}},
  url          = {{http://dx.doi.org/10.1016/S1470-2045(15)70056-2}},
  doi          = {{10.1016/S1470-2045(15)70056-2}},
  volume       = {{16}},
  year         = {{2015}},
}